Showing results (51-60 of 91) with videos related to
Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2012
Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibitionLisa Zimmer, Uwe Hillen, Elisabeth Livingstone, et al.Nature|November 26, 2010
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationRamin Nazarian, Hubing Shi, Qi Wang, et al.European Journal of Nuclear Medicine and Molecular Imaging|April 28, 2020
FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatmentAmir Iravani, Medhat M Osman, Alison M Weppler, et al.Plos One|August 21, 2008
Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancerElizabeth A Musgrove, C Marcelo Sergio, Sherene Loi, et al.Internal Medicine Journal|April 3, 2018
Exploring the feasibility and utility of exome-scale tumour sequencing in a clinical settingBelinda Lee, Ben Tran, Arthur L Hsu, et al.The Lancet. Oncology|July 20, 2014
Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b studyAntoni Ribas, Rene Gonzalez, Anna Pavlick, et al.The Lancet. Oncology|February 4, 2014
Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trialsKeith T Flaherty, Michael Hennig, Sandra J Lee, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2011
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitorsPatrick A Oberholzer, Damien Kee, Piotr Dziunycz, et al.Nature Medicine|March 1, 2024
A gut microbial signature for combination immune checkpoint blockade across cancer typesAshray Gunjur, Yan Shao, Timothy Rozday, et al.Oncotarget|October 22, 2014
TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cellsSelina K Sutton, Jessica Koach, Owen Tan, et al.Pageof 10